1. Optimizing Outcomes in Patients With NSCLC and Liver Metastases

3. Background on Liver Metastases

4. LM as a Negative Prognostic Factor

5. LM as a Negative Prognostic Factor (cont)

6. IMpower150: ICI + Anti-VEGFR + Chemo

7. Patient Management Strategies

8. IMpower150: EGFR or ALK Mutations

9. IMpower150: Liver Metastases

10. ECOG 4599: Carboplatin-Paclitaxel ± Bevacizumab

11. Challenges With Currently Approved ICIs

12. Does PD-L1 Level Correlate With Clinical Factors?

13. Future Possibilities for Bevacizumab-Containing Regimen

14. Clinical Challenges

15. Other Potential Metastatic Sites

16. Key Takeaways

17. Abbreviations